|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis显示文摘Nonalcoholic fatty liver disease(NAFLD) is a condition in which excess fat accumulates in the liver of a patient without a history of alcohol abuse.Nonalcoholic steatohepatitis(NASH),a severe form of NAFLD,can progress to liver cirrhosis and hepatocellular carcinoma.NAFLD is regarded as a hepatic manifestation of metabolic syndrome and incidence has been increasing worldwide in line with the increased prevalence of obesity,type 2 diabetes,and hyperlipemia.Animal models of NAFLD/NASH give crucial information,not only in elucidating pathogenesis of NAFLD/NASH but also in examining therapeutic effects of various agents.An ideal model of NAFLD/NASH should correctly reflect both hepatic histopathology and pathophysiology of human NAFLD/NASH.Animal models of NAFLD/NASH are divided into genetic,dietary,and combination models.In this paper,we review commonly used animal models of NAFLD/NASH referring to their advantages and disadvantages. | Yoshihisa Takahashi Yurie Soejima Toshio Fukusato | 2012 | World Journal of Gastroenterology2012，18，19： | 57 |
| 2 | Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis显示文摘Nonalcoholic fatty liver disease(NAFLD)/nonalcoholic steatohepatitis(NASH) is considered to be a hepatic manifestation of metabolic syndrome, and its incidence is rapidly increasing worldwide. It is currently the most common chronic liver disease. NASH can progress to liver cirrhosis and hepatocellular carcinoma, and may result in liver-related death. Currently, the principal treatment for NAFLD/NASH is lifestyle modification by diet and exercise. However, pharmacological therapy is indispensable because obese patients with NAFLD often have difficulty maintaining improved lifestyles. The pathogenesis of NAFLD/NASH has not been completely elucidated. However, insulin resistance, inflammatory cytokines, and oxidative stress are thought to be important in the development and/or progression of the disease. Currently, insulin sensitizers(thiazolidinediones) and antioxidants(vitamin E) seem to be the most promising therapeutic agents for NAFLD/NASH, and lipid-lowering drugs, pentoxifylline, angiotensin receptor blockers, and n-3 polyunsaturated fatty acids also have promise. However, there is a lack of consensus regarding the most effective and appropriate pharmacotherapy for NAFLD/NASH. Animal experiments suggest that herbal medicines and natural products may be promising therapeutic agents for NAFLD/NASH, but their efficacy and safety are yet to be investigated in human studies. In this paper, we review the existing and potential pharmacological therapies for NAFLD/NASH. | Yoshihisa Takahashi Keiichiro Sugimoto Hiroshi Inui Toshio Fukusato | 2015 | World Journal of Gastroenterology2015，21，13： | 41 |
| 3 | Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis显示文摘Nonalcoholic fatty liver disease(NAFLD), a hepatic manifestation of metabolic syndrome, is the most common chronic liver disease, and the prevalence is rapidly increasing worldwide. Nonalcoholic steatohepatitis(NASH), the severe form of NAFLD, can progress to liver cirrhosis and hepatocellular carcinoma(HCC). Although noninvasive clinical scores and image-based diagnosis for NAFLD have improved, histopathological evaluation of biopsy specimens remains the gold standard for diagnosing NAFLD/NASH. Steatosis, lobular inflammation, and hepatocellular ballooning are all necessary components for the diagnosis of NASH; fibrosis is also typically observed. Other histopathological abnormalities commonly observed in NASH include hepatocellular glycogenated nuclei, lipogranulomas, and acidophil bodies. The characteristics of pediatric NAFLD/NASH differ from adult NAFLD/NASH. Specifically, steatosis and portal inflammation are more severe in pediatric NAFLD, while intralobular inflammation and perisinusoidal fibrosis are milder. Although interobserver agreement for evaluating the extent of steatosis and fibrosis is high, agreement is low for intralobular and portal inflammation. A recently reported histological variant of HCC, steatohepatitic HCC(SH-HCC), showsfeatures that resemble non-neoplastic steatohepatitis,and is thought to be strongly associated with underlying NASH.In this report,we review the histopathological features of NAFLD/NASH. | Yoshihisa Takahashi Toshio Fukusato | 2014 | World Journal of Gastroenterology2014，20，42： | 19 |
| 4 | Spontaneous regression of hepatic inflammatory pseudotumor with primary biliary cirrhosis:Case report and literature review显示文摘肝的煽动性的假肿瘤(IPT ) 是煽动性的房间渗入的增殖的纤维组织描绘的稀罕良性的非肿瘤的损害。IPT 的准确病原学仍然保持不清楚。尽管有全身的煽动性的混乱的 IPT 的协会很好被建立了,有胆管炎的一种特殊关系是显然稀罕的。我们与主要胆汁性肝硬变(PBC ) 报导肝的 IPT 的自发的回归的一个案例。迄今为止,仅仅有 PBC 的 IPT 的二个案例被报导了。在我们的情况中,然而, IPT 在有效治疗导致的 PBC 的胆管炎的改进的功课期间发展了,不同于二个以前报导的案例。我们的案例显示 IPT 的发展也不联系到胆管炎或亢奋的 gamma-globulinemia 的活动,自从我们的案例被证实当胆汁的酶和免疫球蛋白比承认上的相应价值高得多时,没有 IPT 的放射线学的联盟者。我们有二个以前报导的案例的案例的比较建议与 PBC 发生的 IPT 不代表一样的疾病实体或是为 PBC 的一个旁观者。 | Hiroshi Koide Ken Sato Toshio Fukusato Kenji Kashiwabara Noriaki Sunaga Takafumi Tsuchiya Saeko Morino Naondo Sohara Satoru Kakizaki Hitoshi Takagi Masatomo Mori | 2006 | World Journal of Gastroenterology2006，12，10： | 12 |
| 5 | Plexiform angiomyxoid myofi broblastic tumor of the stomach显示文摘Plexiform angiomyxoid myofibroblastic tumor of the stomach is a unique mesenchymal tumor that we first described in 2007.The tumor is very rare,and to date,only 18 cases confirmed by immunohistochemistry have been reported in the literature.The patients' ages ranged from 7 to 75 years(mean,43 years),and the male-to-female ratio was approximately 1:1.Representative clinical symptoms are ulceration,associated upper gastrointestinal bleeding(hematemesis),and anemia.The tumors are located at the antrum in all cases,and grossly,the tumor is whitish to brownish or reddish,and forms a lobulated submucosal or transmural mass.Microscopically,the tumor is characterized by a plexiform growth pattern,the proliferation of cytologically bland spindle cells,and a myxoid stroma that is rich in small vessels and positive for Alcian blue stain.Immunohistochemically,the tumor cells are positive for α-smooth muscle actin and negative for KIT and CD34.Differential diagnoses include gastrointestinal stromal tumor and other mesenchymal tumors of the gastrointestinal tract.Some authors proposed that this tumor should be designated as 'plexiform fibromyxoma',but this designation might cause confusion.The tumor is probably benign and thus far,neither recurrence nor metastasis has been reported. | Yoshihisa Takahashi Masako Suzuki Toshio Fukusato | 2010 | World Journal of Gastroenterology2010，16，23： | 12 |
| 6 | Protein induced by vitamin K absence or antagonist Ⅱ-producing gastric cancer显示文摘Protein induced by vitamin K absence or antagonist Ⅱ(PIVKA-Ⅱ) is a putative specific marker of hepatocellular carcinoma(HCC),but it may also be produced by asmall number of gastric cancers.To date,16 cases of PIVKA-Ⅱ-producing gastric cancer have been reported,2 of which were reported by us and all of which were identified in Japan.There are no symptoms specific to PIVKA-Ⅱ-producing gastric cancer,and the representative clinical symptoms are general fatigue,appetite loss,and upper abdominal pain.Serum alpha-feto-protein(AFP)levels are also increased in almost allcases.Liver metastasis is observed in approximately 80% of cases and portal vein tumor thrombus is ob-served in approximately 20% of cases.Differential diagnosis between metastatic liver tumor and HCC is often difficult.Grossly,almost all cases appear as advanced gastric cancer.Histologically,a hepatoid pattern is observed in many cases,in addition to a moderately to poorly differentiated adenocarcinoma component.The production of PIVKA-Ⅱ and AFP is usually confirmed using immunohistochemical staining.Treatment and prognosis largely depends on the existence of liver meta-stasis,and the prognosis of patients with liver metas-tasis is very poor.PIVKA-Ⅱ may be produced during the hepatocellular metaplasia of the tumor cells. | Yoshihisa Takahashi Tohru Inoue Toshio Fukusato | 2010 | World Journal of Gastrointestinal Pathophysiology2010，1，4： | 4 |
| 7 | Pediatric nonalcoholic fatty liver disease:Overview with emphasis on histology显示文摘Nonalcoholic fatty liver disease(NAFLD) is a disease in which excessive fat accumulates in the liver of a patient without a history of alcohol abuse.This disease includes simple steatosis and nonalcoholic steatohepatitis(NASH).NAFLD/NASH is recognized as a hepatic manifestation of metabolic syndrome.In recent years,pediatric NAFLD has increased in line with the increased prevalence of pediatric obesity.The estimated prevalence of pediatric NAFLD is 2.6%-9.6%,and it is associated with sex,age,and ethnicity.With regard to the pathogenesis of NAFLD,the 'two-hit' hypothesis is widely accepted and oxidative stress is thought to play an important role in the second hit.Although clinical symptoms,laboratory data,and imaging findings are important,liver biopsy is regarded as the gold standard for the diagnosis of NAFLD/NASH.In addition,liver biopsy is essential for assessing the degree of necro-inflammatory change and fibrosis in NASH.Two different types of steatohepatitis(type 1 and type 2 NASH) have been reported,with type 2 NASH being present in as many as 51% of pediatric NAFLD patients.However,we and others have observed that type 1 and 2 patterns commonly overlap.Although pharmacotherapy has been studied in clinical trials,lifestyle modification by diet and exercise remains the mainstay of treatment for NAFLD/NASH. | Yoshihisa Takahashi Toshio Fukusato | 2010 | World Journal of Gastroenterology2010，16，42： | 4 |
| 8 | Expression of HLA class I antigens on hepatocytes in liver disease显示文摘 | Fukusato T Gerber MA Thung SN | 1986 | Am J Pathol1986，123，2： | 1 |
| 9 | Prognostic significance of DNA topoisomerase Ⅱ alpha expression in human hepatocellular carcinoma显示文摘 | Watanuki A Ohwada S Fukusato T | 2002 | Anticancer Res2002，22，2： | 1 |
| 10 | REG4, NEIL2, andBIRC5 gene expression correlates with gamma-radiation sensitivity in patients with rectal cancer receiving radiothrapy 显示文摘 | Kobunai T Watanabe T Fukusato T | 2011 | Antican- cer2011，31，12： | 1 |
| 11 | Coexpression of glucose transporter 1 and matrix metalloproteinase-2 in human cancers显示文摘 | Ito S Fukusato T Nemoto T | 2002 | J Natl Cancer Inst2002，94，14： | 1 |
| 12 | Prognostic significance of DNA topoisomerase II alpha expression in human hepatocellular carcinoma 显示文摘 | Watanuki A Ohwada S Fukusato T | 2002 | Anticancer Res2002，22，2： | 1 |
| 13 | Acute necrotizing encephalopathy with widespread edematous lesions of symmetrical distribution显示文摘 | Mizuguchi M Tomonaga M Fukusato T | 1989 | Acta Neuropathol1989，78，1： | 1 |
| 14 | DualFace:Two-stage drawing guidance for freehand portrait sketching显示文摘Special skills are required in portrait painting, such as imagining geometric structures and facial detail for final portrait designs. This makes it a difficult task for users, especially novices without prior artistic training, to draw freehand portraits with high-quality details. In this paper, we propose dualFace, a portrait drawing interface to assist users with different levels of drawing skills to complete recognizable and authentic face sketches. Inspired by traditional artist workflows for portrait drawing, dualFace gives two-stages of drawing assistance to provide global and local visual guidance. The former helps users draw contour lines for portraits (i.e., geometric structure), and the latter helps users draw details of facial parts, which conform to the user-drawn contour lines. In the global guidance stage, the user draws several contour lines, and dualFace then searches for several relevant images from an internal database and displays the suggested face contour lines on the background of the canvas. In the local guidance stage, we synthesize detailed portrait images with a deep generative model from user-drawn contour lines, and then use the synthesized results as detailed drawing guidance. We conducted a user study to verify the effectiveness of dualFace, which confirms that dualFace significantly helps users to produce a detailed portrait sketch. | Zhengyu Huang Yichen Peng Tomohiro Hibino Chunqi Zhao Haoran Xie Tsukasa Fukusato Kazunori Miyata | 2022 | Computational Visual Media2022，8，1： | 1 |
| 15 | Adenomyoma with goblet and Paneth cells of the ileum显示文摘 | Takahashi Y Fukushima J Fukusato T | 2006 | Pathol Res Pract2006，202，7： | 1 |
| 16 | Genetic classification of combined hepatocellular-cholangiocarcinoma显示文摘 | Hiroaki Fujii Xue Gong Zhu Toshiharu Matsumoto Mitsuhiro Inagaki Yoshihiko Tokusashi Naoyuki Miyokawa Toshio Fukusato Toshimasa Uekusa Tetsuya Takagaki Naomi Kadowaki Toshikazu Shirai | 2000 | Human Pathology2000，，9： | 1 |
| 17 | Sarcomatoid carcinoma with components of small cell carcinoma and undifferentiated carcinoma of the gallbladder 显示文摘 | Takahashi Y Fukushima J Fukusato T | 2004 | Pathol Int2004，54，11： | 1 |
| 18 | Expression of HLA class I antigens on hepatocytes in liver disease显示文摘 | Fukusato T Gerber MA Thung SN | 1986 | Am J Pathol1986，123，2： | 1 |
| 19 | REG4, NEIL2, and BIRC5 gene expression correlates with gammaradiation sensitivity in patients with rectal cancer receiving radiotherapy显示文摘 | Kobunai T Watanabe T Fukusato T | 2011 | Anticancer Res2011，31，12： | 1 |
| 20 | Prevalence of ischemic enterocolitis in patients withacute pancreatitis 显示文摘 | Takahashi Y Fukushima J Fukusato T | 2005 | J Gastroenterol2005，40，8： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员